keyword
MENU ▼
Read by QxMD icon Read
search

Ckd treatment

keyword
https://www.readbyqxmd.com/read/29144803/endocrine-manifestations-of-primary-hyperoxaluria
#1
Shatha Murad, Yuval Eisenberg
OBJECTIVE: Primary hyperoxaluria type 1 (PH1) is a rare metabolic disorder of oxalate overproduction. It is associated with urolithiasis and nephrocalcinosis which progress to ESRD and systemic oxalosis. As oxalate deposits in tissues, non-parathyroid hormone (nonPTH) mediated hypercalcemia, oxalate osteopathy, primary hypothyroidism and primary hypogonadism develop. In this review, we will present a case of PH1 and provide an overview of this clinical entity and its endocrine manifestations...
November 16, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29142980/effectiveness-of-multifaceted-care-approach-on-adverse-clinical-outcomes-in-nondiabetic-ckd-a-systematic-review-and-meta-analysis
#2
Aminu K Bello, Bilal Qarni, Arian Samimi, Julius Okel, Trish Chatterley, Ikechi G Okpechi, Ben Vandermeer, Branko Braam
Introduction: The risk of major adverse events associated with chronic kidney disease (CKD) could potentially be reduced with effective medical interventions. The impact of multifaceted interventions as compared with usual care in patients with nondiabetic CKD is unclear. We performed a systematic review to analyze the impact of multifaceted interventions on reducing the risk of major adverse events in this population. Methods: Systematic review and meta-analysis...
July 2017: KI Reports
https://www.readbyqxmd.com/read/29142968/the-effect-of-renal-function-and-hemodialysis-treatment-on-plasma-vasopressin-and-copeptin-levels
#3
Esmée M Ettema, Judith Heida, Niek F Casteleijn, Lianne Boesten, Ralf Westerhuis, Carlo A J M Gaillard, Ron T Gansevoort, Casper F M Franssen, Debbie Zittema
Introduction: Copeptin is increasingly used in epidemiological studies as a substitute for vasopressin. The effect of renal function per se on copeptin and vasopressin concentrations as well as their ratio have, however, not been well described. Methods: Copeptin and vasopressin levels were measured in 127 patients with various stages of chronic kidney disease, including 42 hemodialysis patients and 16 healthy participants in this observational study. Linear (segmental) regression analyses were performed to assess the association between renal function and copeptin, vasopressin and the C/V ratio...
May 2017: KI Reports
https://www.readbyqxmd.com/read/29142956/hypertension-control-apparent-treatment-resistance-and-outcomes-in-the-elderly-population-with-chronic-kidney-disease
#4
Jean Kaboré, Marie Metzger, Catherine Helmer, Claudine Berr, Christophe Tzourio, Tilman B Drueke, Ziad A Massy, Bénédicte Stengel
Introduction: Chronic kidney disease (CKD) is often associated with poor hypertension control and treatment resistance, but whether CKD modifies the effect of hypertension control on outcomes is unknown. Methods: We studied 10-year mortality and cardiovascular events according to hypertension control status and CKD (glomerular filtration rate <60 ml/min/1.73m(2)) in 4262 community-dwelling individuals (40% men) more than 65 years of age. Results: At baseline, 19% had CKD, and 31...
March 2017: KI Reports
https://www.readbyqxmd.com/read/29141939/dapagliflozin-in-focal-segmental-glomerulosclerosis-a-combined-human-rodent-pilot-study
#5
Harindra Rajasekeran, Heather N Reich, Michelle A Hladunewich, Daniel Cattran, Julie A Lovshin, Yuliya Lytvyn, Petter Bjornstad, Vesta Lai, Josephine Tse, Leslie Cham, Syamantak Majumder, Bridgit B Bowskill, M Golam Kabir, Suzanne L Advani, Ian W Gibson, Manish M Sood, Andrew Advani, David Z I Cherney
BACKGROUND: Focal segmental glomerulosclerosis (FSGS) is an important cause of non-diabetic chronic kidney disease (CKD). Sodium glucose cotransporter-2 inhibition (SGLT2i) therapy attenuates the progression of diabetic nephropathy, but it remains unclear whether SGLT2i provides renoprotection in non-diabetic CKD such as FSGS. OBJECTIVE: The primary aim of this pilot study was to determine the effect of 8 weeks of dapagliflozin on GFR in humans and in experimental FSGS...
November 15, 2017: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/29140528/evaluation-of-renal-function-change-during-first-line-tyrosine-kinase-inhibitor-therapy-for-metastatic-renal-cell-carcinoma
#6
Hiroki Ishihara, Tsunenori Kondo, Hironori Fukuda, Kazuhiko Yoshida, Kenji Omae, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi, Kazunari Tanabe
Background: The change in renal function induced by first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma remains unclear. Methods: One hundred and thirty-four patients were evaluated. Sunitinib (SU) and sorafenib (SO) were administered to 91 (67.9%) and 43 (32.1%) patients, respectively. The change in estimated glomerular filtration rate (ΔeGFR) was calculated as [(eGFR at each time point - pre-treatment eGFR)/pre-treatment eGFR] × 100...
November 13, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29137892/role-of-pyrophosphate-in-vascular-calcification-in-chronic-kidney-disease
#7
Daniel Azpiazu, Sergio Gonzalo, Emilio González-Parra, Jesús Egido, Ricardo Villa-Bellosta
Vascular calcification is a pathology characterized by the deposition of calcium-phosphate in cardiovascular structures, mainly in the form of hydroxyapatite crystals, resulting in ectopic calcification. It is correlated with increased risk of cardiovascular disease and myocardial infarction in diabetic patients and in those with chronic kidney disease (CKD). Vascular smooth muscle cells are sensitive to changes in inorganic phosphate (Pi) levels. They are able to adapt and modify some of their functions and promote changes which trigger calcification...
November 11, 2017: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://www.readbyqxmd.com/read/29137333/preoperative-chronic-kidney-disease-predicts-poor-oncological-outcomes-after-radical-nephroureterectomy-in-patients-with-upper-urinary-tract-urothelial-carcinoma
#8
Hirotake Kodama, Shingo Hatakeyama, Naoki Fujita, Hiromichi Iwamura, Go Anan, Ken Fukushi, Takuma Narita, Toshikazu Tanaka, Yuka Kubota, Hirotaka Horiguchi, Masaki Momota, Koichi Kido, Teppei Matsumoto, Osamu Soma, Itsuto Hamano, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroyuki Ito, Kazuaki Yoshikawa, Atsushi Sasaki, Toshiaki Kawaguchi, Makoto Sato, Chikara Ohyama
Objective: To evaluate the impact of preoperative chronic kidney disease (CKD) on oncological outcomes in patients with upper tract urothelial carcinoma who underwent radical nephroureterectomy. Methods: A total of 426 patients who underwent radical nephroureterectomy at five medical centers between February 1995 and February 2017 were retrospectively examined. Oncological outcomes, including intravesical recurrence-free, visceral recurrence-free, cancer-specific, and overall survival rates (intravesical RFS, visceral RFS, CSS, and OS, respectively) stratified by preoperative CKD status (CKD vs...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137111/effect-of-omega-3-fatty-acid-supplementation-on-plasma-fibroblast-growth-factor-23-levels-in-post-myocardial-infarction-patients-with-chronic-kidney-disease-the-alpha-omega-trial
#9
Martin H de Borst, Leandro C Baia, Ellen K Hoogeveen, Erik J Giltay, Gerjan Navis, Stephan J L Bakker, Johanna M Geleijnse, Daan Kromhout, Sabita S Soedamah-Muthu
Fibroblast growth factor 23 (FGF23) is an independent risk factor for cardiovascular mortality in chronic kidney disease. Omega-3 (n-3) fatty acid consumption has been inversely associated with FGF23 levels and with cardiovascular risk. We examined the effect of marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and plant-derived alpha-linolenic acid (ALA) on plasma FGF23 levels in post-myocardial infarction patients with chronic kidney disease. In the randomized double-blind Alpha Omega Trial, 4837 patients with a history of myocardial infarction aged 60-80 years (81% men) were randomized to one of four trial margarines supplemented with a targeted additional intake of 400 mg/day EPA and DHA, 2 g/day ALA, EPA-DHA plus ALA, or placebo for 41 months...
November 11, 2017: Nutrients
https://www.readbyqxmd.com/read/29137107/effect-of-lanthanum-carbonate-on-coronary-artery-calcification-and-bone-mineral-density-in-maintenance-hemodialysis-patients-with-diabetes-complicated-with-adynamic-bone-disease-a-prospective-pilot-study
#10
Chunhua Zhang, Shixiang Wang, Sumei Zhao, Xiaodong Zhang
BACKGROUND: The incidence of adynamic bone disease (ABD) is increasing. Coronary artery calcification (CAC) may be severe in patients with ABD on maintenance hemodialysis (MHD). The aim of this study was to evaluate the effect of lanthanum carbonate (LC) on CAC and bone mineral density (BMD) in MHD patients with diabetes complicated with ABD. METHODS: A total of 92 MHD cases were divided into the calcium carbonate (CC) and LC groups. Primary outcome measure was the changes in the degree of CAC score (CACS) and BMD in forearm from baseline to 12 months...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29136724/-expert-consensus-for-the-diagnosis-and-treatment-of-patients-with-renal-impairment-of-multiple-myeloma
#11
(no author information available yet)
Renal impairment (RI) is a common complication of multiple myeloma (MM), which is presented as chronic kidney disease (CKD) or acute kidney injury (AKI). The typical pathological feature is cast nephropathy. Presently international system staging (ISS) is used in evaluating MM. Although the classic Durie-Salmon staging system could be still used in clinical practice, it may miss out some patients with renal impairment. For evaluations of RI in MM patients with CKD, it's recommended to assess the estimated glomerular filtration rate (eGFR) by creatinine based formula CKD-epidemiology collaboration (EPI) or modification of diet in renal disease(MDRD) and to stage the renal injuries according to 2013 Kidney Disease Improving Global Outcomes (KDIGO) CKD guidelines...
November 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29132915/human-recombinant-erythropoietin-reduces-sensorimotor-dysfunction-and-cognitive-impairment-in-rat-models-of-chronic-kidney-disease
#12
E E Reza-Zaldívar, S Sandoval-Avila, Y K Gutiérrez-Mercado, E Vázquez-Méndez, A A Canales-Aguirre, H Esquivel-Solís, U Gómez-Pinedo, A L Márquez-Aguirre
INTRODUCTION: Chronic kidney disease (CKD) can cause anaemia and neurological disorders. Recombinant human erythropoietin (rHuEPO) is used to manage anaemia in CKD. However, there is little evidence on the effects of rHuEPO on behaviour and cognitive function in CKD. This study aimed to evaluate the impact of rHuEPO in sensorimotor and cognitive functions in a CKD model. METHODS: Male Wistar rats were randomly assigned to 4 groups: control and CKD, with and without rHuEPO treatment (1050 IU per kg body weight, once weekly for 4 weeks)...
November 10, 2017: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29132440/influence-of-successful-periodontal-intervention-in-renal-disease-inspired-study-protocol-for-a-randomised-controlled-pilot-clinical-trial
#13
Praveen Sharma, Paul Cockwell, Thomas Dietrich, Charles Ferro, Natalie Ives, Iain L C Chapple
BACKGROUND: Patients with chronic kidney disease (CKD) exhibit increased morbidity and mortality which is associated with an increased systemic inflammatory burden. Identifying and managing comorbid diseases that contribute to this load may inform novel care pathways that could have a beneficial impact on the morbidity/mortality associated with CKD. Periodontitis, a highly prevalent, chronic inflammatory disease affecting the supporting structures of teeth, is associated with an increased systemic inflammatory and oxidative stress burden and the successful treatment of periodontitis has been shown to reduce both...
November 13, 2017: Trials
https://www.readbyqxmd.com/read/29131397/a-double-blind-placebo-controlled-multicenter-prospective-randomized-study-of-beraprost-sodium-treatment-for-cats-with-chronic-kidney-disease
#14
M Takenaka, A Iio, R Sato, T Sakamoto, H Kurumatani
BACKGROUND: Chronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated. HYPOTHESIS/OBJECTIVES: To evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compared to placebo. ANIMALS: Seventy-four client-owned cats with naturally occurring CKD. METHODS: Double-blind, placebo-controlled, multicenter, prospective, randomized trial...
November 13, 2017: Journal of Veterinary Internal Medicine
https://www.readbyqxmd.com/read/29130954/effects-of-tolvaptan-addition-to-furosemide-in-normo-and-hyponatremia-patients-with-heart-failure-and-chronic-kidney-disease-stages-g3b-5-a-subanalysis-of-the-k-star-study
#15
Naoto Tominaga, Keisuke Kida, Takayuki Inomata, Naoki Sato, Tohru Izumi, Yoshihiro J Akashi, Yugo Shibagaki
BACKGROUND: Tolvaptan increases free water clearance (aquaresis) and thereby improves hyponatremia. Although hyponatremia on admission is common in patients with congestive heart failure (CHF), little is known regarding the response to tolvaptan in those who also have chronic kidney disease (CKD) with or without hyponatremia. The aim of this subanalysis was to investigate the differences in treatment response between normo- and hyponatremia patients with CHF and CKD stages G3b-5. METHODS: The Kanagawa Aquaresis Investigators Trial of Tolvaptan on HF Patients with Renal Impairment (K-STAR) was a multicenter, open-label, randomized, controlled prospective clinical trial that included 81 Japanese patients with CHF and residual signs of congestion despite oral furosemide treatment (≥40 mg/day)...
November 7, 2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/29128778/circadian-blood-pressure-patterns-and-blood-pressure-control-in-patients-with-chronic-kidney-disease
#16
Nicola Di Daniele, Danilo Alunni Fegatelli, Valentina Rovella, Veronica Castagnola, Marco Gabriele, Angelo Scuteri
BACKGROUND AND AIMS: Hypertension is a major risk factor for chronic kidney disease (CKD), and CKD progression is associated with suboptimal blood pressure (BP) control. Here we evaluate the impact of CKD on the attainment of BP control and the circadian BP profile in older subjects. METHODS: In this observational study, we studied 547 patients referred to the hypertension clinic, of whom 224 (40.9%) had CKD. Blood pressure (BP) control and circadian BP patterns were evaluated by 24-hour ambulatory BP monitoring...
October 26, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/29128444/metabolomics-and-gene-expression-analysis-reveal-down-regulation-of-the-citric-acid-tca-cycle-in-non-diabetic-ckd-patients
#17
Stein Hallan, Maryam Afkarian, Leila R Zelnick, Bryan Kestenbaum, Shoba Sharma, Rintaro Saito, Manjula Darshi, Gregory Barding, Daniel Raftery, Wenjun Ju, Matthias Kretzler, Kumar Sharma, Ian H de Boer
Chronic kidney disease (CKD) is a public health problem with very high prevalence and mortality. Yet, there is a paucity of effective treatment options, partly due to insufficient knowledge of underlying pathophysiology. We combined metabolomics (GCMS) with kidney gene expression studies to identify metabolic pathways that are altered in adults with non-diabetic stage 3-4 CKD versus healthy adults. Urinary excretion rate of 27 metabolites and plasma concentration of 33 metabolites differed significantly in CKD patients versus controls (estimate range-68% to +113%)...
October 31, 2017: EBioMedicine
https://www.readbyqxmd.com/read/29127220/therapeutic-potential-of-micrornas-for-the-treatment-of-renal-fibrosis-and-ckd
#18
Wenshan Lv, Fan Fan, Yangang Wang, Ezekiel Gonzalez-Fernandez, Chen Wang, Lili Yang, George W Booz, Richard J Roman
Chronic kidney disease (CKD), defined as reduced glomerular filtration rate, is increasingly becoming a major public health issue. At the histological level, renal fibrosis is the final common pathway leading to end-stage renal disease, irrespective of the initial injury. According to this view, antifibrotic agents should slow or halt the progression of CKD. However, due to multiple overlapping pathways stimulating fibrosis, it has been difficult to develop antifibrotic drugs that delay or reverse the progression of CKD...
November 10, 2017: Physiological Genomics
https://www.readbyqxmd.com/read/29115800/the-current-role-of-renal-biopsy-in-diabetic-patients
#19
Sheila Bermejo, Julio Pascual, María J Soler
Diabetes Mellitus (DM) is a worldwide health problem due to its high prevalence, incidence and impact on patient morbidity and mortality. Chronic kidney disease (CKD) is one of the most important complications of DM. The indication of renal biopsy in diabetic patients is a widely debated topic and the final decision is usually individualized. The results of renal biopsy in diabetic patients can be classified into three groups: diabetic nephropathy (DN), non-diabetic renal disease (NDRD) or DN plus NDRD (mixed forms)...
November 7, 2017: Minerva Medica
https://www.readbyqxmd.com/read/29107998/impact-of-surgical-parathyroidectomy-on-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd-a-systematic-review-and-meta-analysis
#20
Mugurel Apetrii, David Goldsmith, Ionut Nistor, Dimitrie Siriopol, Luminita Voroneanu, Dragos Scripcariu, Marc Vervloet, Adrian Covic
For more than 6 decades, many patients with advanced chronic kidney disease (CKD) have undergone surgical parathyroidectomy (sPTX) for severe secondary hyperparathyroidism (SHPT) mainly based historical clinical practice patterns, but not on evidence of outcome.We aimed in this meta-analysis to evaluate the benefits and harms of sPTX in patients with SHPT. We searched MEDLINE (inception to October 2016), EMBASE and Cochrane Library (through Issue 10 of 12, October 2016) and website clinicaltrials.gov (October 2016) without language restriction...
2017: PloS One
keyword
keyword
19486
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"